Лечение артериальной гипертензии у детей и подростков


https://doi.org/10.21508/1027-4065-2019-64-1-15-24

Полный текст:


Аннотация

Представлены данные о современных подходах к немедикаментозному и медикаментозному лечению артериальной гипертензии у детей и подростков. Проанализированы рекомендации по лечению артериальной гипертензии Американской ассоциации сердца (2017 г.) и Европейского общества гипертензии (2016 г.). Изложены возможности немедикаментозного воздействия путем изменения диетического рациона и повышения уровня физической  активности. Освящены данные многоцентровых рандомизированных клинических исследований по применению основных групп гипотензивных препаратов у детей и подростков, рекомендации по целевому уровню артериального давления при лечении артериальной гипертензии. Представлены  показания и противопоказания к назначению гипотензивных препаратов: ингибиторов ангиотензинпревращающего фермента, блокаторов рецепторов ангиотензина, блокаторов кальциевых каналов. Пересмотрены  представления о применении β-адреноблокаторов для лечения артериальной гипертензии. Рассматриваются возможности лечения рефрактерной артериальной гипертензии, особенности лечения гипертензии при протеинурии, метаболическом синдроме, дислипидемии.


Об авторе

И. В. Леонтьева
Научно-исследовательский клинический институт педиатрии им. академика Ю.Е. Вельтищева РНИМУ им. Н.И. Пирогова Минздрава России
Россия

Леонтьева Ирина Викторовна – доктор медицинских наук,  профессор, главный научный сотрудник отдела  детской  кардиологии и аритмологии.

125412 Москва,  ул. Талдомская, д. 2.



Список литературы

1. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114 (2 suppl): 555–576.

2. Flynn J.T., Kaelber D.C., Baker-Smith C.M., Blowey D., Carroll A.E., Daniels S.R. et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140(3): e20171904. DOI: 10.1542/peds.2017-1904

3. Lurbea E., Agabiti-Roseic E., Cruickshankd J.K., Dominiczake A., Erdinef S., Hirthg A. et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34(10): 1887–1920. DOI: 10.1097/HJH.0000000000001039

4. Диагностика, лечение и профилактика артериальной гипертензии у детей и подростков. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2009; 8(4): приложение1: 1–32.

5. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 1–98. DOI: 10.1093/eurheartj/ehy339

6. Nerenberg K.A., Zarnke K.B., Leung A.A., Dasgupta K., Butalia S., McBrien K. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can J Cardiol 2018; 34(5): 506–525. DOI: 10.1016/j.cjca.2018.02.022

7. Rapsomaniki E., Timmis A., George J., Pujades-Rodriguez M., Shah A.D., Denaxas S. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014; 383: 1899–1911. DOI: 10.1016/S0140-6736(14)60685-11

8. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens 2014; 32: 2285–2295.

9. Theodore R.F., Broadbent J., Nagin D., Ambler A., Hogan S., Ramrakha S. et al. Childhood to early-midlife systolic blood pressure trajectories: early-life predictors, effect modifiers, and adult cardiovascular outcomes. Hypertension 2015; 66(6): 1108–1115. DOI: 10.1161/HYPERTENSIONAHA.115.05831

10. Torrance B., McGuire K.A., Lewanczuk R., McGavock J. Overweight, physical activity and high blood pressure in children: a review of the literature. Vasc Health Risk Manag 2007; 3(1): 139–149.

11. Farpour-Lambert N.J., Aggoun Y., Marchand L.M., Martin X.E., Herrmann F.R., Beghetti M. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54(25): 2396–2406. DOI: 10.1016/j.jacc.2009.08.030

12. Kelley G.A., Kelley K.S., Tran Z.V. The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials. Prev Cardiol 2003; 6(1): 8–16.

13. Tompkins C.L., Moran K., Preedom S., Brock D.W. Physical activity-induced improvements in markers of insulin resistance in overweight and obese children and adolescents. Curr Diabetes Rev 2011; 7(3): 164–170.

14. Damasceno M.M., de Araújo M.F., deFreitas R.W., de Almeida P.C., Zanetti M.L. The association between blood pressure in adolescents and the consumption of fruits, vegetables and fruit juice – an exploratory study. J Clin Nurs 2011; 20(11–12): 1553–1560. DOI: 10.1111/j.1365-2702.2010.03608.x

15. Moore L.L., Bradlee M.L., Singer M.R., Qureshi M.M., Buendia J.R., Daniels S.R. Dietary approaches to stop hypertension (DASH) eating pattern and risk of elevated blood pressure in adolescent girls. Br J Nutr 2012; 108(9): 1678–1685. DOI: 10.1017/S000711451100715X

16. Saneei P., Hashemipour M., Kelishadi R., Rajaei S., Esmaillzadeh A. Effects of recommendations to follow the dietary approaches to stop hypertension (DASH) diet v. usual dietary advice on childhood metabolic syndrome: a randomized cross-over clinical trial. Br J Nutr 2013; 110(12): 2250–2259. DOI: 10.1017/S0007114513001724

17. Yang Q., Zhang Z, Kuklina E.V., Fang J., Ayala C., Hong Y. et al. Sodium intake and blood pressure among US children and adolescents. Pediatrics 2012; 130(4): 611–619. DOI: 10.1542/peds.2011-3870

18. Resnicow K., McMaster F., Bocian A., Harris D., Zhou Y., Snetselaar L. et al. Motivational interviewing and dietary counseling for obesity in primary care: an RCT. Pediatrics 2015; 135(4): 649–657. DOI: 10.1542/peds.2014-1880

19. Broccoli S., Davoli A.M., Bonvicini L., Fabbri A., Ferrari E., Montagna G. et al. Motivational interviewing to treat overweight children: 24-month follow-up of a randomized controlled trial. Pediatrics 2016; 137(1): e20151979. DOI: 10.1542/peds.2015-1979

20. Chu P.Y., Campbell M.J., Miller S.G., Hill K.D. Anti-hypertensive drugs in children and adolescents. World J Cardiol 2014; 6: 234–244. DOI: 10.4330/wjc.v6.i5.234

21. Dionne J.M., Harris K.C., Benoit G., FeberJ., Poirier L., Cloutier L. et al. Hypertension Canada’s 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension. Can J Cardiol 2017; 33(5): 557–688. DOI: 10.1016/j.cjca.2017.03.007

22. Croxtall J.D. Valsartan: in children and adolescents with hypertension. Paediatr Drugs 2012; 14(3): 201–207. DOI: 10.2165/11208990-000000000-00000

23. Wühl E., Trivelli A., Picca S., Litwin M., Peco-Antic A., Zurowska A. et al.; ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361(17): 1639–1650. DOI: 10.1056/NEJ-Moa0902066

24. Wells T., Blumer J., Meyers K.E. Valsartan Pediatric Hypertension Study Group. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens (Greenwich) 2011; 13(5): 357–365. DOI: 10.1111/j.1751-7176.2011.00432

25. Flynn J.T., Newburger J.W., Daniels S.R., Sanders S.P., Portman R.J., Hogg R.J. et al.; PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 2004; 145(3): 353–359.

26. Webb N.J., Shahinfar S., Wells T.G., Massaad R., Gleim G.W., Santoro E.P. et al. Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int 2012; 82(7): 819–826. DOI: 10.1038/ki.2012.210

27. Gartenmann A.C., Fossali E., von Vigier R.O., Simonetti G., Schmidtko J., Edefonti A. et al. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int 2003; 64(4): 1450–1454.

28. Flynn J.T. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol 2005; 20(5):631–635.

29. Soffer B., Zhang Z., Miller K. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003; 16: 795–800. DOI: 10.1016/S0895-7061(03)00900-2

30. Seeman T., Gilik J., Vondrak K., Simková E., Flögelová H., Hladíková M. et al. Regression of left-ventricular hypertrophyin children and adolescents with hypertension during Ramipril monotherapy. Am J Hypertens 2007; 20: 990–996.

31. Baker-Smith C.M., Benjamin D.K., Califf R.M. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther 2010; 87: 668–671. DOI: 10.1038/clpt.2009.231

32. Shahinfar S., Cano F., Soffer B.A., Ahmed T., Santoro E.P., Zhang Z. et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 2005; 18 (2, pt 1): 183–190.

33. Schaefer F., Coppo R., Bagga A., Senguttuvan P., Schlosshauer R., Zhang Y. et al. Efficacy and safety of valsartan in hypertensive children 6 mon to 5 years of age. J Hypertens 2013; 31(5): 993–1000. DOI: 10.1097/HJH.0b013e32835f5721

34. Schaefer F., Litwin M., Zachwieja J., Zurowska A., Turi S., Grosso A. et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 2011; 29(12): 2484–2490. DOI: 10.1097/HJH.0b013e32834c625c

35. Trachtman H., Hainer J.W., Sugg J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 2008; 10: 743–750. DOI: 10.1111/j.1751-7176.2008.00022

36. Hazan L., Hernández Rodriguez O.A., Bhorat A.E., Miyazaki K., Tao B., Heyrman R. et al. Assessment of Efficacy an Olmesartan in Pediatric Hypertension Study Group. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 2010; 55(6): 1323–1330. DOI: 10.1161/HYPERTENSIONAHA.109.147702

37. Simonett G.D., von Vigier R.O., Konrad M., Rizzi M., Fossali E., Bianchetti M.G. Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatr Nephrol 2006; 21(10): 1480–1482.

38. Trachtman H., Frank R., Mahan J.D., Portman R., Restaino I., Matoo T.K. et al. Clinical trial of extended release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003; 18: 548–553. DOI: 10.1007/s00467-003-1134-0

39. Sica D.A., Carter B., Cushman W., Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich) 2011; 13: 639–643. DOI: 10.1111/j.1751-7176.2011.00512

40. Karnes J.H., Cooper-DeHoff R.M. Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther 2009; 7: 689–702. DOI: 10.1586/erc.09.31

41. Li J.S., Flynn J.T., Portman R., Davis I., Ogawa M., Shi H. et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr 2010; 157(2): 282–287. DOI: 10.1016/j.jpeds.2010.02.042

42. Meyers R.S., Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clin Ther 2011; 33: 1331–1356. DOI: 10.1016/j.clinthera.2011.09.003

43. Poirier L., Lacourcière Y. The evolving role of β-adrenergic receptor blockers in managing hypertension. Can J Cardiol 2012; 28: 334–340. DOI: 10.1016/j.cjca.2012.04.001

44. Batisky D.L., Sorof J.M., Sugg J., Llewellyn M., Klibaner M., Hainer J.W., et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 2007; 150(2): 134–139. DOI: 10.1016/j.jpeds.2006.09.034

45. Sorof J.M., Cargo P., Graepel J., Humphrey D., King E., Rolf C. et al. β-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo controlled trial. Pediatr Nephrol 2002; 17(5): 345–350. DOI: 10.1007/s00467-002-0851-0

46. Poirier L., Tobe S.W. Contemporary use of beta-blocker: clinical relevance of subclassification. Can J Cardiol 2014; 30: S9–15. DOI: 10.1016/j.cjca.2013.12.001

47. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–2219. DOI: 10.1093/eurheartj/eht151

48. Daugherty S.L., Powers J.D., Magid D.J., Tavel H.M., Masoudi F.A., Margolis K.L. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635–1642. DOI: 10.1161/CIRCULATIONAHA.111.068064

49. Narayan H., Webb D.J. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep 2016; 18(5): 34. DOI: 10.1007/s11906-016-0643-8

50. Williams B., MacDonald T.M., Morant S., Webb D., Sever P., McInnes G. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment or drugresistant hypertension(PATHWAY-2): a randomised, doubleblind, crossover trial. Lancet 2015; 386(10008): 2059–2068. DOI: 10.1016/S0140-6736(15)00257-3

51. White W.B., Turner J.R., Sica D.A. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., 2013. J Am Soc Hypertens 2014; 8(10): 743–757. DOI: 10.1016/j.jash.2014.06.005

52. Redwine K., Howard L., Simpson P., Li S.H., Yan K., James L. et al. Effect of placebo on ambulatory blood pressure monitoring in children. Pediatr Nephrol 2012; 27(10): 1937–1942. DOI: 10.1007/s00467-012-2191-z

53. Juhola J., Magnussen C.G., Berenson G.S., Venn A., Burns T.L., Sabin M.A. et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium. Circulation 2013; 128: 217–224. DOI: 10.1161/CIRCULATIONAHA.113.001614

54. Urbina E.M., Williams R.V., Alpert B.S., Collins R.T., Daniels S.R., Hayman L. et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009; 54(5): 919–950. DOI: 10.1161/HYPERTENSIONAHA.109.192639

55. Martino F., Puddu P.E., Pannarale G., Colantoni C., Martino E., Zanoni C. et al. Hypertension in children and adolescents attending a lipid clinic. Eur J Pediatr 2013; 172(12): 1573–1579. DOI: 10.1007/s00431-013-2082-8


Дополнительные файлы

Для цитирования: Леонтьева И.В. Лечение артериальной гипертензии у детей и подростков. Российский вестник перинатологии и педиатрии. 2019;64(1):15-24. https://doi.org/10.21508/1027-4065-2019-64-1-15-24

For citation: Leontyeva I.V. Treatment of hypertension in children and adolescents. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2019;64(1):15-24. (In Russ.) https://doi.org/10.21508/1027-4065-2019-64-1-15-24

Просмотров: 184

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1027-4065 (Print)
ISSN 2500-2228 (Online)